Plain-English translation of NCT06169956 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study that tracks how well Nivolumab (also called OPDIVO) works when combined with standard chemotherapy before surgery in patients with early-stage, resectable lung cancer. Researchers are collecting real-world information from patients across Germany who are already scheduled to receive this combination treatment. The study aims to understand how effective this treatment is and how it affects patients' outcomes and quality of life.
Doctors want to learn more about how well this medication performs when combined with chemotherapy as a pre-surgery treatment in actual clinical practice, rather than just in controlled research settings. Understanding real-world effectiveness helps doctors better treat future patients with early-stage lung cancer.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive the combination treatment (Nivolumab plus chemotherapy) that your doctor has already planned for you—this part is standard care, not experimental. In addition to your regular medical appointments, you would complete patient questionnaires at certain points to share how you are feeling and how the treatment is affecting your quality of life. The study simply collects information from your regular medical visits and your responses to these surveys to help researchers understand how this treatment works in real patients across Germany.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
Germany
Sponsor
Bristol-Myers Squibb
Enrollment target
~400 participants
Started
November 2023
Primary completion
September 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
BMS Study Connect Contact Center www.BMSStudyConnect.com
Bristol-Myers Squibb
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.